MaxCyte Analyst Price Targets - Benzinga

MaxCyte Inc

MXCTNASDAQ

Trade with Public

Trade with Public

$1.70

-0.0264-1.53%

Últ. Act.: Oct 30, 9:23 AM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

MaxCyte Analyst Price Targets - Benzinga

MaxCyte Analyst Price Targets

Wall Street analyst price targets and consensus rating for MaxCyte (MXCT).

Price Target Range — 6 Quarters

Analyst Consensus — 5 Analysts

3Buy

2Hold

Consensus RatingOverweight# Analysts5Avg. Consensus PT$8Upside to Avg. PT+354.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 25, 2026	Craig-Hallum	Matt Hewitt	PT Cut	Buy	$7→$5
Aug 11, 2025	BTIG	Mark Massaro	Downgrade	Buy→Neutral	—
Aug 7, 2025	William Blair	Matt Larew	Downgrade	Outperform→Market Perform	—
Jul 22, 2025	Stephens & Co.	Helfey Hannah	Assumes	Overweight	$6
Mar 12, 2025	Stifel	Daniel Arias	PT Cut	Buy	$11→$9
Apr 23, 2024	Stephens & Co.	Jacob Johnson	Maintained	Overweight	$11
Mar 13, 2024	Stephens & Co.	Jacob Johnson	Maintained	Overweight	$11
Mar 13, 2024	BTIG	Mark Massaro	PT Cut	Buy	$10→$8
Nov 29, 2023	Craig-Hallum	Matt Hewitt	Initiate	Buy	$7

Analyst Ratings News

PRO
Craig-Hallum Maintains Buy on MaxCyte, Lowers Price Target to $5

Craig-Hallum analyst Matt Hewitt maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price target from $7 to $5.

Benzinga Newsdesk

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Avi Kapoor

PRO
BTIG Downgrades MaxCyte to Neutral

BTIG analyst Mark Massaro downgrades MaxCyte (NASDAQ:MXCT) from Buy to Neutral.

Benzinga Newsdesk

PRO
William Blair Downgrades MaxCyte to Market Perform

William Blair analyst Matt Larew downgrades MaxCyte (NASDAQ:MXCT) from Outperform to Market Perform.

Benzinga Newsdesk

PRO
Stephens & Co. Assumes MaxCyte at Overweight, Announces Price Target of $6

Stephens & Co. analyst Helfey Hannah assumes MaxCyte (NASDAQ:MXCT) with a Overweight rating and announces Price Target of $6.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on MaxCyte, Lowers Price Target to $9

Stifel analyst Daniel Arias maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price target from $11 to $9.

Benzinga Newsdesk